Literature DB >> 10708081

Core decompression in atraumatic osteonecrosis of the hip.

C J Lavernia1, R J Sierra.   

Abstract

Core decompression for osteonecrosis of the femoral head continues to be a controversial procedure. We report the results of core decompression in the treatment of hip osteonecrosis. Forty-two patients (67 hips) were evaluated. Minimum follow-up was 2 years. Preoperative outcome instruments were assessed. Volume of involvement (%) from magnetic resonance imaging was assessed. Failure was described as a total hip arthroplasty (THA). Mean patient age was 40.26 years. The average clinical and radiologic follow-up was 40.7 months and 33.1 months. The average Harris Hip Scores preoperatively and postoperatively were 49 and 58. None of the hips classified as Ficat I progressed to THA, whereas 17% of Ficat II hips and 66% of Ficat III hips progressed to THA. Our results demonstrate no relationship between the volume of involvement of the femoral head or the location of the lesion in progression to collapse. Staging with the Ficat classification demonstrated the most statistically significant correlation with progression to THA. The SF-36 scores at last follow-up on our patients were significantly worse than patients undergoing THA.

Entities:  

Mesh:

Year:  2000        PMID: 10708081     DOI: 10.1016/s0883-5403(00)90132-3

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  14 in total

1.  Analysis of outcome of avascular necrosis of femoral head treated by core decompression and bone grafting.

Authors:  Smit N Shah; Chirag S Kapoor; Maulik R Jhaveri; Paresh P Golwala; Sagar Patel
Journal:  J Clin Orthop Trauma       Date:  2015-05-01

2.  A current review of core decompression in the treatment of osteonecrosis of the femoral head.

Authors:  Todd P Pierce; Julio J Jauregui; Randa K Elmallah; Carlos J Lavernia; Michael A Mont; James Nace
Journal:  Curr Rev Musculoskelet Med       Date:  2015-09

3.  Management of osteonecrosis of the hip complicated with fracture: a case report.

Authors:  Ycj Chua; Nn Wazir; Ck Chiu; Ba Kareem
Journal:  Malays Orthop J       Date:  2012-06

Review 4.  Which factors influence preservation of the osteonecrotic femoral head?

Authors:  Jay R Lieberman; Stephen M Engstrom; R Michael Meneghini; Nelson Fong SooHoo
Journal:  Clin Orthop Relat Res       Date:  2012-02       Impact factor: 4.176

5.  SAS weekly rounds: avascular necrosis.

Authors:  Thomas W Hamilton; Susan M Goodman; Mark Figgie
Journal:  HSS J       Date:  2009-03-18

6.  Trabecular metal screw implanted for avascular necrosis of the femoral head may complicate subsequent arthroplasty surgery.

Authors:  N Papapietro; A Di Martino; G Niccoli; A Palumbo; G Salvatore; F Forriol; V Denaro
Journal:  Eur J Orthop Surg Traumatol       Date:  2013-07-17

7.  Magnetic resonance imaging criteria of successful core decompression in avascular necrosis of the hip.

Authors:  S Radke; S Kirschner; V Seipel; C Rader; J Eulert
Journal:  Skeletal Radiol       Date:  2004-06-23       Impact factor: 2.199

Review 8.  Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.

Authors:  Samir K Ballas; Muge R Kesen; Morton F Goldberg; Gerard A Lutty; Carlton Dampier; Ifeyinwa Osunkwo; Winfred C Wang; Carolyn Hoppe; Ward Hagar; Deepika S Darbari; Punam Malik
Journal:  ScientificWorldJournal       Date:  2012-08-01

9.  Nontraumatic avascular necrosis of the femoral head : Arthroscopic and navigation-supported core decompression.

Authors:  Jan Theopold; Sarah Armonies; Philipp Pieroh; Pierre Hepp; Andreas Roth
Journal:  Oper Orthop Traumatol       Date:  2019-11-28       Impact factor: 1.154

10.  Outcome after tantalum rod implantation for treatment of femoral head osteonecrosis: 26 hips followed for an average of 3 years.

Authors:  Sokratis E Varitimidis; Apostolos P Dimitroulias; Theophilos S Karachalios; Zoe H Dailiana; Konstantinos N Malizos
Journal:  Acta Orthop       Date:  2009-02       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.